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FEATURE ARTICLE
SCIENCE FORUM
RIPOSTE: a framework for
improving the design and
analysis of laboratory-based
research
Abstract Lack of reproducibility is an ongoing problem in some areas of the biomedical sciences.
Poor experimental design and a failure to engage with experienced statisticians at key stages in the
design and analysis of experiments are two factors that contribute to this problem. The RIPOSTE
(Reducing IrreProducibility in labOratory STudiEs) framework has been developed to support early
and regular discussions between scientists and statisticians in order to improve the design, conduct
and analysis of laboratory studies and, therefore, to reduce irreproducibility. This framework is
intended for use during the early stages of a research project, when specific questions or hypotheses
are proposed. The essential points within the framework are explained and illustrated using three
examples (a medical equipment test, a macrophage study and a gene expression study). Sound study
design minimises the possibility of bias being introduced into experiments and leads to higher
quality research with more reproducible results.
DOI: 10.7554/eLife.05519.001
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Introduction
Laboratory-based studies play a central role in
preclinical biomedical research, encompassing
a diverse range of techniques and spanning
a broad range of fields across the biomedical
sciences. For example, investigations of the
biological pathways underpinning drug response
or microbial pathogenesis, the assessment of
safety and efficacy of interventions, and the
discovery of biomarkers all rely on laboratory-
based methods for at least some stages of
observation, measurement and/or processing.
Despite this key role, approaches to the design,
analysis and reporting of laboratory studies can
be highly varied. Moreover, the frequently
dynamic nature of laboratory based research
can mean that studies are often complex and
may consist of various exploratory components,
which may not be fully documented when results
are published. This can lead to a lack of trans-
parency about the research methodology, and
may prevent any results and findings from being
successfully reproduced.
Lack of reproducibility (or ‘irreproducibility’) is
an acknowledged problem within biomedicine
that has recently been gaining increased atten-
tion (Begley and Ellis, 2012; Begley, 2013; The
Economist, 2013; Macleod et al., 2014).
Attempts to independently confirm or follow-up
on spurious research findings waste time, money
(which may have public or charitable origins) and
resources, and also raises ethical concerns.
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Initiatives aiming to address irreproducibility in
the biomedical sciences are therefore underway
(Errington et al., 2014; Morrison, 2014). Initial
efforts have largely focussed on improving
reporting standards from research publications.
For example, both Science and Nature have
recently introduced new reporting guidelines
that aim to improve the transparency of research
disseminated in their journals (Nature, 2013;
McNutt, 2014). Attempts to harmonise and
improve reporting standards across particular
types of study have also been made. The
Minimum Information About a Microarray Exper-
iment (MIAME) (Brazma, 2009) initiative targets
experimental protocols in microarray experi-
ments and other ‘omics’ studies, while the
REMARK guidelines (Altman et al., 2012) focus
on the appropriate and transparent use of
statistical methods in tumour marker prognostic
studies. A recent report from the Institute of
Medicine in the US also focuses on ‘omics’
studies (Institute of Medicine, 2012). Several
other relevant guidelines for reporting health
related research can be found through the
EQUATOR network (equator-network.org). A
common theme in these guidelines is the
appropriate and transparent reporting of statis-
tical methods.
Whilst the above initiatives aim to improve
transparency in published laboratory based re-
search, a focus only on the reporting of studies
does not address other key factors that may also
contribute to irreproducibility. For instance, a re-
cent retraction of a MIAME compliant study
(Sebastiani et al., 2011) demonstrates that
targeting reporting standards alone cannot pre-
vent irreproducibility. A large number of other
retractions have also been highlighted (www.
retractionwatch.com), increasing the focus on
what contributes to the problem and how to
tackle it (Irizarry et al., 2005; Baggerly and
Coombes, 2009; Prinz et al., 2011; Sebastiani
et al., 2011; Begley and Ellis, 2012; Lambert
and Black, 2012; Parker and Leek, 2012;
Freedman and Inglese, 2014).
Several factors may lead to irreproducibility in
laboratory studies. As highlighted above, poor
reporting can limit the ability to accurately
reproduce results. Although general methodol-
ogy and procedures are usually reported, key
details needed to guarantee that an entire
analysis pipeline can be reproduced are often
missing, such as information about a study’s
methods and/or analysis. This may include in-
formation about the modality of data handling
and manipulation, version of software and/or
libraries used, and implementation of the statis-
tical methods.
Issues relating to the generation of data,
including study design and methods to minimise
the introduction of bias, may also contribute to
irreproducibility. Any bias introduced into a study
often cannot be removed and may impact on the
results in ways that may be difficult to quantify
(Bogardus et al., 1999). These issues may stem
from practices within the laboratory itself; for
example, unwanted variation posed by batch
effects or other confounding variables can sys-
tematically and irreversibly distort the measure-
ments taken within a study unless appropriately
accounted for at the design stage. Technical
issues relating to the analysis may also lead to
errors; for instance, incorrectly distinguishing
between repeated and independent measure-
ments can increase the likelihood of obtaining
false positive or false negative results.
A lack of formal guidance on the process of
laboratory study design may also give rise to
irreproducibility. Although in some respects
laboratory-based research is highly regulated,
such regulation largely relates to materials, pro-
cesses and ethics rather than focussing on
aspects of study design or improving methodo-
logical rigor. For example, procedures and
protocols must be approved by the Control of
Substances Hazardous to Health Regulations
(COSHH), while pre-clinical pharmaceutical and
medical device research is governed very strictly
by Good Laboratory Practice (GLP) regulations.
Clinical studies using human samples are subject
to ethical review, research governance and the
International Committee on Harmonisation of
Good Clinical Practice (ICH GCP) and may also
be subject to the Human Tissue Act (2004).
Certain laboratory work is also conducted under
accreditation from UKAS and CPA or to ISO/BSI
standards. In contrast to other methods of
experimental research such as clinical trials,
however, none of these regulations specifically
addresses study design and there is often no
formal requirement to produce a study-specific
protocol or analysis plan in advance of data
collection.
The existing culture where novel research is
rewarded over and above attempts to replicate
findings may also contribute to irreproducibility.
Those who attempt to replicate results currently
face expenses in terms of time and resources,
and can find it hard to publish their findings
whether they confirm or not (Ioannidis, 2005,
2006). This may contribute to the well-known
phenomenon of ‘publication bias’, where positive
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but potentially one-off or chance novel results
disproportionately enter the literature at the
expense of negative findings. Failing to ade-
quately document negative findings can also lead
to publication bias, and may lead to others
unnecessarily repeating the work in future. Bias
towards publication of statistically significant
results has been shown to be substantively
greater for observational and laboratory-based
studies than for randomised clinical trials (East-
erbrook et al., 1991).
It is now generally accepted that poor study
design is a major problem in laboratory based
research (Collins and Tabak, 2014). While most
scientists will have received training in experi-
mental design in an abstract form, it may be
difficult to put it into practice, especially when
some experiments can be conducted by a single
researcher. Currently this poor design is being
picked up at the reporting stage as was the case
in clinical research some 30 years ago. For
instance, in the 1980s weaknesses in the report-
ing of clinical studies led to a number of
initiatives to improve statistical awareness and
understanding. As a result, reporting guidelines
were developed (Moher et al., 2001; Schulz
et al., 2010) to promote the reporting of key
methodological components and results that
enable study bias to be assessed and to support
evidence synthesis. This recognition of the key
role of statistical principles in study design and
analysis has resulted in integrated and critical
involvement by statisticians in all aspects of
clinical trials. Ethical concerns have led regulatory
bodies to impose strict standards concerning all
aspects of the design, analysis and reporting of
clinical trials, which ensure that they are properly
planned and implemented.
A clinical trial can be considered the equiva-
lent of a single experiment to test a specific
hypothesis. These single experiment trials require
their own funding and generally result in at least
two publications; the protocol and the results on
completion. By contrast in basic science it is very
unusual for the results of a single experiment to
be published in isolation. It is more common to
find a series of experiments presented, linked
with inductive and deductive reasoning. This
tendency to present a broad range of linked
experiments and results in a single publication
has been a barrier to the development of
appropriate reporting guidelines. Some journals
are now actively promoting the submission of
short follow-on reports (the Research Advance in
eLife) or breakthrough articles where simple but
important questions are addressed (Corey et al.,
2014). Although the methods employed in
laboratory studies are diverse and experiments
can be completed within very short time frames,
much can be learnt from the standards upheld in
trials. Trials are designed and managed by
regular consultation within full, multidisciplinary
teams. Such teams can involve health-
economists, computer scientists and statisticians,
as well as clinicians, scientists and/or qualitative
researchers. Input from the full interdisciplinary
team at all stages of a study helps to ensure that
trials are optimally designed, making efficient use
of resources and avoiding potential difficulties at
the analysis stage. Trials are long term projects
where protocols are first established, participants
are recruited and then endpoints are measured.
By contrast, in laboratory research many experi-
ments may be conducted in parallel at many
levels within a research group, and the rigid
clinical trial design structure would not allow the
flexibility required for new research to emerge.
We assert that greater consideration of the
principles of good experimental design coupled
with early and regular discussion amongst all the
members of the research team will help improve
the design, analysis and reporting of laboratory
based studies. This, in turn, should lead to higher
quality data and reproducible research. Such
improvements will require a gear change from
all involved in the field especially from research
funders.
To support the implementation of such an
integrated approach we have developed the
RIPOSTE framework, which draws together key
elements of laboratory study design and analysis
that may contribute to reproducibility. The
framework is accompanied by three hypothetical
case-studies to demonstrate the discussion that
may follow the consideration of each prompt
point. The overall aim of the framework is to
support discussion within a multidisciplinary re-
search team (including the statistician), to ensure
that potential sources of bias and/or variability
have been considered and, where possible,
eliminated at the design stage. We are aware
that scientific advances can be made through
a mix of inductive and deductive reasoning. This
framework is focussed to support more discus-
sion in the deductive stages when hypotheses
and specific questions are proposed.
The framework was developed in two stages.
The NIHR Statistics Group held a laboratory
research studies day, during which the initial
project was conceived and major elements for
the framework identified. A prompt-list using
items commonly encountered in reporting
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guidelines was then constructed and revised to
be relevant for laboratory experiments at the
design stage. For the second stage we invited 12
statisticians and 12 laboratory scientists to a one-
day workshop where the framework was piloted
as a means to facilitate discussion on aspects of
study design and analysis. The framework was
trialled in small groups: two scientists and two
statisticians worked in each group and the
framework was tested using examples supplied
by the scientists. At the end of the workshop
feedback was obtained and suggested modifica-
tions to the framework were collated. Modifica-
tions were made and further feedback was
obtained from the RIPOSTE consortium via an
online survey. In the survey delegates were asked
to score the inclusion of items on a 0–10 scale
(high score to retain item). Items receiving
a median score less than 8 were removed, and
any which had been scored 0 by at least one
respondent, irrespective of the median score,
were revised if necessary in line with the respond-
ents’ comments. Suggestions on the structure
and presentation were also incorporated.
We present here a framework to support early
discussions within a multidisciplinary research
team, which should consist of both scientists
and statisticians. The framework contains a com-
prehensive list of the details that facilitate re-
production of research and is intended to
promote discussion about key aspects of the
design, conduct and analysis of a planned labo-
ratory study. The framework offers a series of
prompts that raise pertinent questions to facili-
tate shared understanding of the research and
the environment in which it is being undertaken.
The catch-all term ‘laboratory studies’ covers
a wide range of study types (Box 4), and some
aspects of the framework will not always be
applicable in all studies. Similarly, some aspects of
the framework will not always be relevant for
discussion with statisticians, but nevertheless
concern issues that still require careful consider-
ation within the research team. We see this
framework as a useful toolbox in the hands of
the scientist, which takes and builds upon many
points raised in recent journal and topic specific
publication guidelines. Our workshop confirmed
that it can take a long time for a statistician to fully
understand the basic designs of a series of
experiments when first presented. This is often
due to lack of familiarity with the field of
application. We felt that using some carefully
selected case-studies to demonstrate how the
prompts in the framework can be used would
help both statisticians and scientists in its
implementation. We have, therefore, included
three hypothetical case studies as examples which
have been selected to cover a broad spectrum of
biomedical laboratory settings. The first (Box 1) is
a study of combinations of components of
automated medical dosing equipment, where
the motivation is to look for equivalent perfor-
mance. The second study (Box 2) examines
macrophage activity when cells are infected with
bacteria and treated with a drug. This experiment
illustrates replicate measurement, treatment and
infection control contrasts and plate or batch
effects. The third (Box 3) is a gene expression
study in patients with hypertension (cases) and
without hypertension (controls), where the aim is
to identify genes that are differentially expressed.
This example allows us to illustrate multiple
hypothesis testing and a variety of sources of
batch effects from tissue processing through to
RNA analysis. The framework is presented in
Table 1; this sets out the major prompts for topics
to be considered and gives some brief notes for
each. The following sections follow the headings
in Table 1 and provide a more detailed break-
down and discussion of items from the frame-
work, clarifying our recommendations.
Research aims and objectives,
specific outcomes and hypotheses
Aims and objectives
The first stage of any study design should involve
clarifying key details such as the aims and
objectives, and the outcome(s) that will be
measured. Early specification of the primary and
any secondary objectives helps to ensure that the
key goals can be appropriately addressed within
a study by steering the necessary planning and
resources towards tackling these issues. Often,
multiple relevant and related objectives exist, but
it may not be possible or desirable to adequately
address them all within a single study. Resources,
therefore, may need to be allocated according to
the priority of each objective, and if any
objectives cannot be adequately addressed it
may be desirable to narrow down the focus of the
study or to initiate further studies/collaborations
to address the open issues. Note that decisions
about which objectives should be prioritised over
others may fundamentally impact on the best
study design to use. The objectives need to be
agreed upon at the outset to ensure the best and
most efficient use of available resources.
Example(s): In the elastomer pump study in
Box 1, the researchers ideally want to assess
whether the new equipment performs as well as
Masca et al. eLife 2015;4:e05519. DOI: 10.7554/eLife.05519 4 of 27
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Box 1. Example: Elastomer pump
study
A study is planned to assess a new type of disposable
elastomer pump and catheter for use in delivering
anaesthetic directly to wounds following major surgery.
The study aims to assess whether the new pump and
catheter—or combinations of the new pump and catheter
with an existing pump and catheter—achieve an accept-
able flow rate over time (i.e., where an ‘acceptable’ flow
rate is defined as within 15% of the set rate). The
researchers also wish to assess whether the performance
of the equipment declines after with reuse.
Methods and materials: The experimental set-up is
presented in Box 1 Figure 1. In order to mimic clinical
practice, the flow rate will be set to 4 ml/hr, and each
experiment will run over a period of 48 hr. Automated
weight measurements of the pump will be taken every 2 hr
via a laptop, and concurrent measurements of the room
temperature will also be made as temperature may impact
upon the flow. Each type of pump (P = existing pump; p =
new pump) is to be tested with each type of catheter (C =
existing catheter; c = new catheter). Four experiments will
be run simultaneously over four units, with each experi-
ment repeated three times before changing equipment
(i.e., each experiment will be run in triplicate). Due to
limited study resources, only four pumps and four
catheters of each type are available for use.
Design: Box 1 Table 1 illustrates two possible arrange-
ments of the pump/catheter combinations over the 4
units. Design A runs a particular combination over all 4
units at the same time before switching to the next
combination, while Design B tests the four different
combinations of pumps and catheters simultaneously
before alternating the order of the combinations over the
units after each set of triplicate experiments.
DOI: 10.7554/eLife.05519.003
Box 1 Figure 1. Equipment set-up for elastomer pump experiment.
DOI: 10.7554/eLife.05519.005
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the existing equipment, and whether the perfor-
mance of the equipment degrades over time.
The amount of equipment available for use in the
study is limited, however, so it may be sensible to
prioritise one objective over the other unless
both can be satisfactorily addressed with suffi-
cient statistical power.
Outcomes interventions and predictors of
interest
The outcomes being measured should clearly
relate to a study’s objectives, and need to be
chosen and prioritised accordingly. Primary out-
comes are defined when undertaking hypothesis
testing when the aim is to detect a specified
effect. Secondary outcomes can also be tested,
but the results from such tests will be interpreted
as hypothesis generating rather than confirma-
tory. Any sample size calculation will be based on
the primary outcome. If there are multiple primary
outcomes a correction for multiple testing will be
required, which will increase the required sample
size for the study. Outcomes therefore need to be
decided upon upfront, to ensure that an informed
sample size calculation can be made.
Example(s): In the macrophage study in Box 2,
the researchers want to assess the cumulative level
of production for each of 10 cytokines over a 24 hr
period. This study has 10 primary outcomes, and
any sample size calculation would need to assume
that (at least) 10 tests will be performed. The
researchers also wish to compare levels between
specific cytokines by measuring their ratios; these
ratios may be viewed as secondary outcomes. If
the estimated power for the study is too low (or,
to paraphrase, the estimated sample size required
is too large), the number of outcomes being
assessed may have to be limited or reprioritised. A
distinction should be drawn between the primary
and secondary outcomes when reporting the
findings from the study, with an acknowledgement
that the assessment of the secondary outcomes
may not be sufficiently powered.
Research questions/hypotheses
Study hypotheses indicate how specific objec-
tives will be addressed in a study, by spelling out
the specific propositions and/or tests that will be
assessed and how. The criteria used to address
the objectives can have a major impact on all
aspects of a study, from its design through to the
interpretation of its results. Specifying the hy-
potheses upfront therefore ensures that these
key details are decided upon at an early stage,
and helps focus aspects of the study planning
and design on tackling these questions.
Once at the reporting stage of a study, stating
the hypotheses also plays an important role in
preserving transparency about the full set of
questions and/or tests addressed. All relevant
hypotheses that were assessed should be
reported regardless of whether the results
obtained were positive or negative (or ‘null’). A
distinction should also be made between the
initially planned tests and any additional findings
Box 1 Table 1. Two potential study designs in which either (a) four pumps and four catheters of the same type are tested
simultaneously or (b) pump and catheter types are balanced during each 48 hr period of data collection, assuming only four
pump-catheter units can be used concurrently and each is tested for 48 hr, three times in succession
Arrangement Duration Bench 1 Bench 2 Bench 3 Bench 4
Suboptimal design with potential for confounding
1 48 hrs × 3 P C P C P C P C
2 48 hrs × 3 P c P c P c P c
3 48 hrs × 3 p C p C p C p C
4 48 hrs × 3 p c p c p c p c
Optimal, balanced design
1 48 hrs × 3 P C P c p C p c
2 48 hrs × 3 P c P C p c p C
3 48 hrs × 3 p c p C P c P C
4 48 hrs × 3 p C p c P C P c
There are four benches of equipment being tested, each with one of each type of pump and one of each type of catheter (P = existing pump;
p = new pump, C = existing catheter; c = new catheter).
DOI: 10.7554/eLife.05519.004
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Box 2. Example: Macrophage
Study
A series of experiments are planned to characterise
macrophage activity (cytokine production and apoptosis)
when cells which are infected with bacteria are treated
with a drug. Blood will be taken from multiple volunteer
donors to obtain peripheral blood mononuclear cells from
which differentiated macrophages are produced. The
macrophages will be infected with a specific dose of
bacteria and treated with a drug. The cytokine production
and apoptosis will be measured at intervals over 24 hr.
The panel of 10 cytokines will be measured by a multiplex
bead system. Each donor will be processed with internal
controls so the four combinations of infection status
(infected/mock infected) and treatment (drug treatment/
control) will be measured.
Research Question: Does treatment with a specific drug to
cells infected with bacteria affect macrophage immune
function measured by cytokine production and apoptosis?
The basic experimental design will include:
1. The assessment of baseline cytokine production in
infected and mock infected macrophages.
2. The time course of cytokine production following the
infection point, captured by measuring levels every 2 hr.
3. The matched design ensures that cells from each
donor can be studied for response to both infection
and treatment. Exactly half of the infected and half of
the mock infected macrophages are treated with the
drug and this is balanced over all donors.
4. The four combinations of treatment and infection will
be processed in parallel on the samples.
Box 2 Figure 2 illustrates two possible ways that macro-
phages from just two donors might be arranged, for
incubation in a single experiment on two eight well
sections of a plate. Each subject has macrophages grown
in eight wells, four of these will be infected with the same
bacteria, and four will be mock infection controls. Two of
the infected and two of the mock infected will be treated
with the drug. Hence for each donor the measurement of
variables under each condition is done twice (i.e., in
duplicate). Arrangements A and B show a total of four
possible plate arrangements. Some arrangements have
conditions or donors clustered or organised into rows or
columns. The two plates for ‘A’ make it easy for the
infectious agent to be dosed out in one block, whereas ‘B’
has all the wells to be treated with the drug in a single
column. In three of the plates, wells from different donors
are never direct neighbours; however, the infection is
done in blocks or pairs of neighbours. The diagram shown
here shows only a part of a larger plate. Plate sizes of 24 or
96 well plates are available for use here; therefore multiple
plates need to be used. The bead system for measuring
cytokine levels uses assays which are automated, however,
the assessment of apoptosis involves visual inspection and
counting of cells. The colour of the medium indicates
exactly which samples are infected and which are treated,
which means the measurements cannot be taken ‘blind’ to
the treatment.
DOI: 10.7554/eLife.05519.006
Box 2 Figure 1. Production of differentiated macrophages from donor samples.
DOI: 10.7554/eLife.05519.007
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that were not part of the original test hypotheses.
Exploratory and/or post-hoc analyses can play an
important role in generating hypotheses for
further study, but results based on these should
generally be regarded with caution pending
further validation. Alternatively a two-stage de-
sign could be used where exploratory findings
can be investigated in new experiments within
the same proposal. This approach is commonly
encountered in ‘omics’ studies where a large
number of variables are considered in the
discovery stage and the ‘best’ of these carried
forward for replication in new samples or
validation in new experiments using a different
method of measurement.
Note that some studies may not be designed
to test a specific hypothesis; for example, pilot or
feasibility studies aiming to establish and/or
assess a novel assay. These studies, nevertheless,
still have their own specific objectives, and these
objectives need to be defined upfront (e.g., by
clarifying what outcomes will be measured and
defining any success/failure criteria).
Example(s): In the elastomer pump study in
Box 1, the researchers aim to assess whether the
new pump and catheter achieve acceptable flow
rates over time. There are potentially numerous
ways to define ‘acceptable’, such as a requirement
that all flow rate measurements have to lie within 4
ml/hr ± 15% (i.e., 0.6 ml/hr), or allowing some
measurements to lie outside these bounds so long
as the mean flow rate lies within them. Alterna-
tively, the researchers may prefer to test whether
the new pump and/or catheter (or any combina-
tion involving the new pump or catheter) performs
equivalently to the existing pump and/or catheter.
In this latter scenario, an ‘equivalence test’ might
be performed. Equivalence tests usually assess an
alternative hypothesis that a new and an existing
intervention are equivalent (versus a null that they
are not) by measuring whether the difference in
means between the two interventions (and its
confidence interval) lies within pre-specified par-
ticular limits. In this study, the hypotheses may
therefore be laid out as follows:
H0A: The 95% confidence interval for the differ-
ence in mean flow rates between new and existing
pumps does not lie within 0 ml/hr ± 0.6 ml/hr.
H1A: The 95% confidence interval for the
difference in mean flow rates between new and
existing pumps lies within 0 ml/hr ± 0.6 ml/hr.
H0B: The 95% confidence interval for the
difference in mean flow rates between new and
existing catheters does not lie within 0 ml/hr ±
0.6 ml/hr.
H1B: The 95% confidence interval for the
difference in mean flow rates between new and
existing catheters lies within 0 ml/hr ± 0.6 ml/hr.
H0C: The 95% confidence interval for the
difference in mean flow rates between any
Box 2 Figure 2. Infection and treatment of donor macrophages.
DOI: 10.7554/eLife.05519.008
Masca et al. eLife 2015;4:e05519. DOI: 10.7554/eLife.05519 8 of 27
Feature article Science forum | RIPOSTE: a framework for improving the design and analysis of laboratory-based research
combination of new pump and/or catheter and
the existing pump and catheter does not lie
within 0 ml/hr ± 0.6 ml/hr.
H1C: The 95% confidence interval for the
difference in mean flow rates between any
combination of new pump and/or catheter and
the existing pump and catheter lies within 0 ml/hr
± 0.6 ml/hr.
These hypotheses confirm the key (primary)
questions of interest that will be tackled within
Box 3. Example: Gene expression
study using RNA-seq
A study is designed to examine differences in gene
expression in kidney tissue taken from human subjects
who exhibit a hypertensive phenotype and those who do
not. Gene expression will be assessed using RNA
sequencing (RNA-seq), which quantifies the expression of
both genes and the RNA transcripts produced by genes.
Each gene can have multiple transcripts—in humans there
are approximately 213,000 known transcripts produced by
∼62,000 genes.
Aims of the study: To identify genes that are differentially
expressed in hypertensive patients compared to normo-
tensive controls. This study will function as a discovery
stage to pick up differentially expressed genes to take
forward for evaluation in a larger sample.
Research Question/Hypotheses: The aim will be to
identify transcripts and genes that differ in expression
between cases and controls. A hypothesis will be tested
for each transcript to assess whether or not it associates
with the disease status. A transcript would be declared as
differentially expressed if the log2 fold difference between
cases and controls is statistically significant after ac-
counting for multiple testing using the false-discovery
rate.
Outcomes of interest: The primary outcome is the
expression level for each transcript or gene; there will be
multiple of these (10,000 s). The measurement of the
outcome will involve three stages. First the kidney tissue
samples are collected and the RNA extracted and
assessed for quality using the RNA Integrity Number (RIN),
secondly samples are then to be sent to a bioscience
company for sequencing. Finally the sequence data is
received from the company and a toolkit such as Tuxedo
will be used for data processing. There is the potential to
report on the use of standard protocols in each of these
steps.
Materials and Techniques: There are SOPs for the RNA
extraction and the methods employed within the bio-
science company. The material will need to be run in
batches, so a mix (random or balanced) of cases and
controls will be sent in each batch and each batch will
contain at least one common sample to assist in the
control of batch effects. The quality of the RNA (as it
arrives at the company) will be a predictor of the quality of
the sequencing. The sample processing and source of the
samples (i.e., the preparation before sending for se-
quencing) may mean that there are systematic (batch)
differences between cases and controls.
Software: Specialist software exists for each stage of this
planned analysis. The Tuxedo suite is designed to process
the raw data output from the sequencing. PEER has been
developed to identify and correct for sources of variation.
The statistical analysis will be done using R Bioconductor.
A workflow diagram to indicate how the options for each
program were set at each stage of the data processing
and analysis will be constructed during the study and will
be used at the analysis and reporting stage.
Constraints: The main constraint is the cost of the
sequencing, hence the preference is to opt for fewer
subject samples so sequencing can be done at a higher
coverage. The maximum number of samples to be
processed is around 40.
Randomisation and Blinding: There is no treatment to be
applied. However cases and controls will be randomly
mixed in batches for shipping to the sequencing
company. The bioscience company will be blind to the
case control status.
Statistical Analysis: There are two groups, cases and
controls, all analyses will adjust for the confounders age,
sex and body mass index. The Limma package in R
Bioconductor fits linear models to each gene/transcript,
then ‘normalises’ across genes and estimates p-values
using an empirical Bayes estimator. The multiple testing
will be accounted for with the FDR correction. The
correction will be for the full number of transcripts
analysed (i.e., post all ‘Quality control’ (QC) criteria).
Sequencing uncertainty is reflected in low expression
values so genes with uncertain reads are likely to not meet
the threshold. The QC requirements are that a transcript
must be expressed in a minimum number of samples to
be included for further analysis.
Validation: To ensure the results are not due to a technical
artefact the most significant results will be validated using
a different technology (the same samples run through
a different technique).
DOI: 10.7554/eLife.05519.009
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the study, illustrate how the interventions will be
assessed, and define the criteria by which to
discriminate between positive and null results.
Study planning
Logistical considerations
This section of the framework addresses aspects
of the study which might impact on the extent of
statistical support required. In some cases,
scientists may have limited access to a statistician,
and whilst we would argue that statisticians
should play an integral role in the research team,
we accept there may be some instances in which
the opportunities for them to provide advice and
input are rare. Therefore it is useful to consider
early on whether statistical support might be
required during the planning and conduct of the
study. If there is limited statistical support then
this may limit the complexity of the analytical
approach that can be recommended.
Giving early thought to the means by which
data will be collected and managed during the
study can be vital to reproducibility, whilst also
impacting on the resources required. Construct-
ing a well-designed, fully validated database
should ensure good quality data are collected
and may reduce delays in detecting errors.
Collecting additional data regarding data quality
(sometimes referred to as ‘meta-data’) can be
helpful to the statistician at the analysis stage.
For instance, it is a good idea to indicate the
reason why a data value is missing.
Example: In the study in Box 3, it would be
a good idea to collect meta-data regarding the
batch numbers and date(s) on which the samples
were processed.
Materials and techniques
The design of a study clearly depends on the
materials and equipment available for use. All
studies have resource constraints and, as described
in section A, these need to be discussed in order to
ensure that the key hypotheses can be appropri-
ately addressed. Other restrictions concerning the
materials and equipment can also impact on study
design.
Laboratory equipment and methods
Financial constraints are the most commonly
encountered limiting factor, which in turn may
lead to limited access to facilities. However,
particular equipment may also be limited in
terms of the number of units that can be
processed within the available timeframe and/or
in a particular batch. If the equipment or
resources available for use are heavily con-
strained and not sufficient to provide an ade-
quate sample size for the primary research
question identified in section A it may be
preferable to revisit and redefine the study’s
objectives, hypotheses and/or outcomes to be
measured in some other way, rather than carrying
out an underpowered study.
Example: Box 1 presents a study where
the number of units of equipment available to
test is strictly limited. The experimenters could
consider redefining how they assess an ‘accept-
able’ flow rate (e.g., specifying a minimum
number of measurements that must fall within
set boundaries, rather than testing for equiva-
lence or statistically significant differences).
Alternatively, the researchers may decide to go
ahead with the study as originally planned, with
the acceptance that it will be unlikely to deliver
a conclusive answer to the primary research
questions. In this scenario, the study could serve
to generate pilot-data to assist the planning of
a future follow-up study, and/or to contribute
a wider meta-analysis of other, sufficiently similar
studies.
Configuration and standardisation of
materials and methods
Processing samples in different batches or across
different pieces of equipment frequently
Box 4. Examples of laboratory
studies
What do we mean by ‘laboratory study’?
c A study in which any aspect of the procedure or analysis
is carried out in a research facility/lab.
c May be in vivo (e.g., imaging) or in vitro (e.g., cell
culture).
c Includes both experimental and observational studies,
but excludes interventional trials*.
c May involve estimation, hypothesis generation or
hypothesis testing/confirmation.
c Can be small (e.g., within a single lab) or large scale
(e.g., multi-centre genome-wide association studies).
*Specific guidance is available for interventional trials,
however many of the RIPOSTE recommendations will be
relevant
DOI: 10.7554/eLife.05519.010
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Table 1. RIPOSTE discussion framework
Item Prompt/Consideration
Details (relevance of question will depend
on study type)
Research aims, objectives, specific outcomes and hypotheses
Aims and objectives Define the key aims of the study What does the study ultimately aim to show?
What are the primary and any secondary
objectives?
Outcomes, interventions and
predictors of interest
Identify the variables and quantities/
qualities of interest that will be
measured (these may be different for
each hypothesis)
What is the primary outcome/response variable?
Are there any secondary outcomes you also wish to
measure and/or assess?
What are the key interventions/groups/predictors
you will be testing?
Research questions/Hypotheses List the research question(s) that will be
addressed and/or any hypotheses that
you would like to test
The research question(s) should be defined in such
a way that they
- relate directly to the study objectives
- relate to a specific outcome (or set of
outcomes) and specific comparisons/
predictors
Each hypothesis should
- be clearly testable
- indicate what signifies a positive result for
example, what is the minimum effect you
would deem important?
Study planning
Logistical considerations Ethical approval Will ethical approval be required for the study?
- Will statistical support be required for the
ethics application?
Statistical support What level of ongoing statistical support is
available for this study?
Data collection and management How will the data be recorded and stored—will this
require construction of a database?
What steps will be taken to validate the data
entered against what was collected?
Who will be responsible for data entry and
validation?
Will any additional information (‘meta data’) be
recorded to indicate data quality?
Materials and techniques Laboratory equipment and methods What specialist equipment and/or techniques will
be used?
Are there any aspects of these that may impact or
limit the design of the study?
Configuration and standardisation of
materials and methods
Is there an accepted or validated way to measure
the outcomes for this specific study or preliminary
work be required to determine this?
What are the possible sources of variation or
systematic bias between samples/batches/
observers/laboratories/centres?
Are any aspects susceptible to systematic variation
and/or bias? What steps will be taken to minimise
measurement bias and variation with consideration
to:
- Technical factors—such as sample collection,
processing, storage and analysis?
Table 1. Continued on next page
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Table 1. Continued
Item Prompt/Consideration
Details (relevance of question will depend
on study type)
- Biological factors—which may include the
effects of comorbidities, diet, medications,
stress, biological rhythms etc, on the
measurement variable?
Possible steps to consider in addressing these
sources of variation might be the use of existing
standards for sample processing or analysis (e.g.,
BRISQ, ISO, ASTM or CLSI), equipment calibration
and maintenance, user training, randomisation of
interventions.
Software What software (if any) will be used during data
processing/collection/storage?
What software will be used during data
analysis—will specialist software be required?
Does the software conform to any quality
assurance standards, if applicable?
Is the software up-to-date?
What constraints/limits are there to the
available resources?
What constraints are there? For example, due to
cost and/or time
- Are there any limits in terms of the available
equipment (e.g., number of plates/chips) or
materials (e.g., binding agents/gels)?
- What would be the maximum number of
samples that could be used/processed given
the available resources and time?
Study design
Design Units of measurement What are the sampling units in the study (e.g.,
blood samples from individuals)?
Will the units be organised according to any
structure (e.g., onto plates, chips, and/or into
batches) or clustered/correlated in any way (e.g.,
samples from different centres), or within families,
matched or paired samples/measurements?
Will any repeated or replicate samples be taken?
For example, any measurements over time; any
biological replicates; any technical replicates.
Are there any inclusion/exclusion criteria?
Randomisation Will any interventions or conditions be allocated at
random to the units?
- If so, how? (e.g., method of random allocation
and process of generating random numbers)
- If not, why not?
Are there any other possible confounders (e.g.,
batches or plates) to which the units may need to
be randomly allocated?
Blinding (masking) Will blinding be used? If not, why not?
Who will be blinded and how?
How will allocation be concealed and how will
masking be maintained?
Under what circumstances will the data be
unblinded?
Groups, treatments, and other
predictors of interest
What are the primary groups or treatments of
interest?
Table 1. Continued on next page
Materials and techniques
(Continued)
Configuration and standardisation of materials and
methods (Continued)
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Table 1. Continued
Item Prompt/Consideration
Details (relevance of question will depend
on study type)
What is your control or comparison group?
Are there multiple independent variables to assess
simultaneously (for example, treatment and time)?
If so, will a factorial design be used (involving
testing all levels of each variable with all levels of
each other)?
Are there any interactions of interest (which may,
for example, lead to factorial designs)?
Use of analytical controls What analytical controls will be used? For example,
qualitative (positive/negative) and/or quantitative
quality controls (QCs); comparative/normalisation
controls
How will the controls be used/for what purpose?
Other potential biases, confounders and
sources of variability
Will you take any steps to minimise any
background noise/variation?
Will you measure and take into account any
potential confounding variables? For example, the
age and sex of any participants; batch/plate/chip
effects; etc.
Sample size considerations Sample size will depend on the primary objective
of the study, whether the aim is to test hypotheses,
estimate a quantity with specified precision or
assess feasibility
Hypothesis testing:
- Is there a single pre-specified primary
hypothesis? Is a correction for multiple testing
required?
- What signifies a positive result (e.g., the
minimum effect size, margin of agreement)?
- What existing data are available to base the
sample size calculation on? (e.g., SD of
outcome)
- What power and overall level of significance will
be used? Will one or two tailed tests be used?
Feasibility, pilot and proof of concept:
- Understanding sources of variation (e.g.,
standard deviation of the outcome)
▪ The sample size needs to be large enough to
give an accurate estimates of any
components of variation
- Estimating with precision (e.g., proportion of
samples that pass QC)
▪ What is the acceptable precision (e.g., width
of confidence interval) required?
- Preliminary proof of effect (e.g., superiority of
a new cell extraction technique)
▪ What probability needs to be set to observe
the correct ordering of your outcomes?
▪ What level of significance would provide
enough evidence to progress to fully
powered study?
Planned analysis
Data assessment and preparation QC criteria What pre-specified criteria will be used to assess
data from quantitative analytical QCs?
Table 1. Continued on next page
Design (Continued) Groups, treatments, and other predictors of interest
(Continued)
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Table 1. Continued
Item Prompt/Consideration
Details (relevance of question will depend
on study type)
What pre-specified criteria will be used to assure
the reproducibility of results?
- Will any thresholds be set to screen or
benchmark data quality (e.g., setting
a maximum coefficient of variation that would
be deemed acceptable)?
Data verification Have you allowed time for data validation and
correction to be completed prior to analysis?
Data normalisation/correction Will the data be normalised or transformed in any
way? If so, how?
Outliers What methods and criteria will be used to identify
any outlying data?
Statistical methods Describe the different analyses to be
performed
Which models or tests will be used (e.g., t-tests;
ANOVA; mixed effects models etc)?
- Do these methods appropriately handle any
repeated or correlated measurements?
What assumptions do the statistical methods rely
upon? How will these be assessed? Do the data
require any transformation?
Which comparisons will be made? For example,
will all pairs of treatments be compared, or will
each treatment just be compared to a control?
What covariates will be adjusted for?
If applicable, what model terms will be fitted, for
example, which main effects and interactions,
which fixed and/or random effects?
Will sensitivity analyses be performed to assess the
validity of the findings?
Missing data What might be the reasons for missing data?
How will missing data be handled, for example, will
missing data points be excluded or imputed?
Multiple testing Will a correction for multiple testing be required? If
so, how many tests will be accounted for?
Which adjustment for multiplicity will be used, for
example, Tukey, Bonferroni, false-discovery rate
Interim analysis Will interim analyses be performed (before the full
number of samples dictated by the sample size
calculation has been collected)? If so, for what
purpose (e.g., to update the required sample size)?
Have any necessary adjustments to the sample size
been made to account for the interim analysis?
Replication and/or validation Is there an intention to replicate the results (e.g., in
an independent set of samples)?
In there an intention to validate the results (e.g.,
using a different technique or method of analysis)?
Reporting results
Guidelines/standards Identify relevant reporting standards What are the most appropriate reporting
guidelines or standards that apply to the study
design (e.g., BRISQ, MIFlowCyt and see www.
equator-network.org). Identifying reporting
standards at the planning stage helps to ensure
that the information required to be reported is
collected during the study and/or produced during
the analysis of the data.
This framework is intended to support discussion within the research team as a whole, including the statistician.
DOI: 10.7554/eLife.05519.002
Data assessment and
preparation (Continued)
QC criteria (Continued)
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introduces technical variability into a study, yet is
often unavoidable. These potential sources of
variability need to be anticipated and even
studied in advance, and steps taken at the design
stage to avoid confounding technical variation
with any particular groups or comparisons of
interest (see later sections on ‘Other potential
biases, confounders and sources of variability’
and ‘Randomisation’).
Equipment and/or experimental methods and
procedures may need prior validation before use
within a study. Appropriate configuration of
methods and equipment can help to minimise
unwanted variation between different experiments
and units and, hence, ensure that measurements
generated in a study are sufficiently accurate and
reproducible. Other factors such as appropriate
maintenance of equipment or training of staff to
use specialised equipment may also impact.
There are a number of organisations that
provide information to help researchers identify
appropriate means of performing quantitative
and qualitative quality assurance. In particular the
World Health Organisation laboratory quality
management system training toolkit is a compre-
hensive and freely available online resource
(http://www.who.int/ihr/training/laboratory_quality/
doc/en/). Guidelines and standards are also avail-
able from the Clinical and Laboratory Standards
Institute (http://clsi.org/standards/) and the US
Food and Drug Administration (http://www.fda.
gov/downloads/Drugs/Guidances/ucm070107.pdf).
These guidelines are routinely used in accredited
industry and medical laboratories and provide
valuable information about many ‘gold standard’
laboratory practices.
Example: In the macrophage example in Box 2,
the bead arrays require prior validation; to do this,
external information about typical standards for
the equipment (such as acceptable coefficients of
variation) may need to be sought and/or de-
termined. As the configuration of equipment often
affects the variability of measurements recorded
within a study, any validation steps may also
impact on sample size and power calculations.
Study design
Units of measurement
Experimental units are the entities that receive
a given ‘treatment’; it should be possible for two
different experimental units to receive two
different treatments of study conditions. Sam-
pling units are the entities upon which measure-
ments will be made. The experimental units can
usually be considered to be independent of one
another, so increasing the number of
experimental units measured in a study usually
increases the amount of independent information
sampled. In contrast, any repeat or replicated
measurements taken on the units do not contrib-
ute additional independent information, but can
nevertheless help to gauge measurement un-
certainty and/or stabilise estimates of inherently
variable measurements. Repeated measurements
may also be used to answer additional questions
of interest. An important consideration concern-
ing the experimental units is the definition of any
inclusion or exclusion criteria.
Example(s): In Box 1, each combination of
a specific pump and a specific catheter on a single
equipment bench makes up an experimental unit
(see Box 1 Figure 1). There are four benches of
measuring equipment on each of which four
different combinations of new/old pump and
new/old are tested, to produce 16 experimental
units. Each unit is tested three times to give three
replicate experiments. During each replicate
experiment, measurements will be taken on the
units at 2 hr intervals over 48 hr periods; each
individual measurement made during each ex-
periment can be considered a sampling unit. The
sampling units will help to provide precise
estimates of the mean flow rate in a given
experiment, and may also contribute information
about whether the equipment degrades in
performance over time. However, since they are
all collected from the same experimental unit,
they cannot be considered independent of each
other; failure to correct for this in the analysis
would artificially inflate the power of the test and
potentially give misleading results (we expand on
this issue below under ‘Statistical methods’:
Describing the different analyses to be
performed).
In the study in Box 3, the sampling units refer
to samples taken from individual volunteer
donors. A single sample is taken from each
donor, so in this case the sampling units are
independent of each other and the sample size
for the analysis is the total number of sampling
units. The aim is to compare gene expression
between hypertensive and normotensive individ-
uals; therefore, both hypertensive and normo-
tensive must be defined along with any
other restrictions on co-morbidity or age and
gender.
Randomisation
Randomisation plays a crucial role in protecting
studies from known and unknown sources of
variation, bias and confounding. Moreover,
implementation of an appropriate randomisation
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strategy can also begin to produce evidence of
causality in experiments. Randomisation is al-
ready widely used in clinical trials during the
allocation of treatments to units, but it serves the
same fundamental purposes in laboratory set-
tings involving the direct manipulation of any
experimental treatments or conditions. Although
implementing a randomisation scheme can be
cumbersome to employ and may involve added
complexity within a study, the potential benefits
it provides offer researchers protection against
future claims of unconscious bias and should
directly lead to enhanced reproducibility. A
randomisation plan should therefore be devised
wherever possible.
While randomisation is a simple concept in
principle, in practice it may need to be employed
as a joint component of the design implementa-
tion. In the simplest case where there are no
groupings or balancing factors to consider,
a simple randomisation procedure can be
employed. If the experiment needs to be
conducted in batches then randomisation should
be employed within each batch with a balanced
number randomly selected to each treatment
group in each batch. The same consideration
needs to take place in a study using case control
samples with a random selection of cases and
controls to each batch. More complicated
designs with two factors (e.g., treatment group
and time) such as the Latin square, use random
permutations of rows and columns to maintain
the balance.
Note that randomisation can also play an
important role even in studies that do not involve
any direct manipulation of experimental condi-
tions or interventions. For example, in observa-
tional studies the effects of potentially
confounding factors such as batch effects can
be alleviated via careful use of randomisation.
Example(s): The study in Box 3 aims to analyse
kidney tissue samples from hypertensive and
normotensive patients using RNA sequencing.
RNA-sequencing may be susceptible to batch
effects, however, so care should be taken to
randomise both case and control samples to each
batch to avoid confounding any potential differ-
ences in gene expression between cases and
controls with any differences between batches.
The way that macrophage differentiation is
shown in Box 2 Figure 1 would suggest that
conditions may vary if donors are processed in
a series rather than in parallel. However, this
experimental design does control for between
batch variation as each donor’s differentiated
macrophages are infected and treated
concurrently.
In the study in Box 1, there are multiple
‘treatments’ (i.e., combinations of new/existing
pump with new/existing catheter) to test on each
of the four equipment benches. This is an
example of a study where it may be desirable
to manually control the order in which units
receiving each treatment are tested rather than
using a fully randomised design. For instance,
Box 1 Figure 1 shows one potential, manually
allocated design, in which every combination of
pump and catheter is tested across the four
benches at any one time, and where the order of
running the combinations is different on each
bench. This design avoids biasing measurements
on any particular combination due to any
potential time-dependent effects/drift (i.e., as
all combinations are always tested at the same
time); in addition, it allows each combination to
be tested with both the unused and used version
of each pump, and both the unused and used
version of each catheter. Note that although this
arrangement is not strictly random, a random
process may be used to select which components
are used together at the starting point. Alterna-
tive arrangements, such as completely random-
ising the combinations over the benches, or
manually arranging the combinations without
regard to potential confounders (e.g., at the
convenience of the experimenters), would be
unlikely to balance the combinations over all
potentially confounding factors in this relatively
small scale study, and may be inferior to
a carefully planned, manually allocated design.
Blinding
Blinding (or ‘masking’) aims to guard against
potential bias within a study by concealing
information about the allocation of treatments
or interventions from the individuals invol-
ved—such as patients, experimenters and/or
analysts. Awareness of the true allocation of
treatments may consciously or unconsciously
influence the behaviour of those involved,
thereby biasing evidence in favour or one
treatment over another. Blinding is especially
important if qualitative judgement makes up any
part of the measurement process.
Example(s): In example study 1, blinding may
be implemented by concealing the pump and
catheter types, if possible, from the experimenter
involved in setting up the equipment. Any study
analysts may also be blinded, for example, by
using codes to reflect intervention types in the
resulting datasets. Note that it may not be
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possible to fully blind everyone involved in this
study, particularly if the two types of pumps and/
or catheters in Box 1 have obviously different
appearances. In this scenario, one potential way
of maintaining the blinding would be to conceal
which of the pumps and catheters are the new
and existing models (and, therefore, which are
the experimental treatments and which are the
controls). Nevertheless, even if the experiment-
ers cannot be blinded in this study, plans should
be put into place to blind any analysts involved.
In the study in Box 2, the experimenter should
ideally be blinded to the infection status of the
cells and to the treatment type.
Groups, treatments and other pre-
dictors of interest
Most studies involve making at least one form of
comparison between groups or interventions of
interest. Comparator groups—usually called ‘con-
trol’ groups—may be positive or negative in
nature (i.e., active or inactive respectively),
depending on the aims of the study. For instance,
a negative control group may be included to
assess whether an experimental treatment has
a greater effect than a placebo, while a positive
control group might be used to assess whether
the experimental treatment is superior to an
existing treatment. These controls, data from
which contribute to statistical assessment of the
research question, are distinct from analytical
controls used during data collection to check that
laboratory processes are running as expected (see
section on ‘Use of analytical controls’, below).
Often, it may be of interest to compare
experimental groups under different conditions
or alongside one or more additional factor of
interest. Where studies contain more than one
factor of interest (including the main experimental
groups), they may be considered to have a ‘facto-
rial’ design if all combinations of the levels of each
factor are tested. Factorial studies provide an
efficient means of examining the effects of
multiple factors within a study, because each
experimental unit contributes information towards
all factors of interest. In addition, they also enable
the potential effects of interactions to be in-
vestigated, which allow the effects of one variable
to differ depending on the value of another.
Example: The Box 2 example may also be
considered a factorial experiment, because it
assesses the effects of both bacterial infection
and drug treatment on macrophage activity
simultaneously. Here, the factorial nature of the
study allows the researchers to assess whether
the effect of the drug differs depending on
whether the cells are infected with bacteria
(i.e., whether there is an interaction between
drug treatment and bacterial infection). In this
study, each factor of interest (‘bacterial infection’
and ‘drug treatment’) is to be validated against
a negative control (‘mock infected cells’ and ‘no
treatment’ respectively). The controls here serve
to enable claims to be made about any poten-
tially causal effects of the factors of interest. For
instance, if the drug treatment was compared to
a pre-treatment or baseline measure instead of
a control, no information about what could or
would have happened in absence of treatment
would be available (for example, perhaps mac-
rophage activity could have changed naturally
between the two time-points).
Use of analytical controls
Analytical controls tend to be used to validate
practices within an experimental assay, helping
to ensure that measurements are accurate and
may be interpreted correctly. Analytical controls
may be required for each variable or condition in
the experiment, for quality control (QC) purposes
and/or to gauge and adjust for background
variation that may systematically influence certain
sets of measurements (see Table 2 and the ‘QC’
section for further details).
Example: In the elastomer pump study in Box 1,
temperature measurements made during data
collection can be used as a form of normalisation
control to obtain temperature-adjusted esti-
mates of flow rate.
Other potential biases, confounders
and sources of variability
Potential sources of bias and variability need to
be anticipated upfront—at the design stage of
a study—in order to avoid or account for their
effects. Systematic sources of variation can often
be tackled via careful study design; for example,
by balancing and/or randomising treatment arms
over potentially confounding variables (such as
plates or batches, or having multiple observers/
experimenters involved in data collection). Sim-
ilarly, potential biases may be avoided by
ensuring experimental runs are conducted under
homogeneous conditions wherever possible
(such as under a fixed temperature), and that
measurements are consistently made (e.g., by
using properly calibrated equipment). If any
unwanted sources of variation cannot be con-
trolled, it may be possible to adjust for their
effects during analysis if the key variables are
measured during the study (Stegle et al., 2012).
Note that, as suggested above, an additional
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source of variation may occur where multiple
researchers are involved in conducting an exper-
iment or in any aspect of the measurement. This
is often seen as a negative aspect of an
experiment where the goal is to reduce error as
far as possible. However, one positive aspect of
this is that results can give an indication of how
robust the experiment is in a wider context.
Ultimately, some level of variation should be
anticipated to occur amongst operators or sites
and this needs to be reported and accounted for
(Barnhart et al., 2007; Maecker et al., 2011).
Example(s): In the Box 1 example, temperature
cannot be controlled between experiments or
time points, but plans have been made to measure
it concurrently with the flow rates. As such, any
confounding effects of temperature can be con-
trolled at the analysis stage by including temper-
ature as a covariate. As this study has a hierarchical
design (i.e., where measurements will be taken on
units across multiple experiments and over se-
quential time-points within an experiment), there
will also be multiple sources of variation that need
to be accounted for during analysis (such as
‘between time-points within an experiment’ and
‘between experiments on the same unit’).
Sample size considerations
Sample size calculations aim to establish the
minimum sample size that a study requires in
order to be in a strong position to answer the
primary research question. The primary research
question may take the form of a statistical
hypothesis test, an estimate with specified pre-
cision, or to obtain evidence for proof of concept
(POC). With a statistical hypothesis test the aim is
to control for two forms of error; type 1 in which
the null hypothesis is rejected when it is true
(false positive), and the type 2 error in which the
null hypothesis is not rejected when the alterna-
tive is true (false negative). The most common
error levels to adhere to are 5% for a type 1 error
and 10% or 20% for a type 2. When the type 2
error is 20% we have an 80% chance (or power) of
rejecting the null when the stated alternative is
true. In the precision context, the aim is to
estimate a population parameter of interest such
as the standard deviation of an outcome, or an
event or prevalence rate. In this form of study,
the aim is to control the expected standard error
of the estimate derived from the sample. POC
studies are typically conducted to obtain some
preliminary evidence that a treatment/
intervention works. One approach is to calculate
the sample size that will give a sufficiently high
probability (90–95%) to observe the correct
ordering of the primary outcome of the
treatment/intervention and control group. If the
estimate for the primary outcome is favourable
for the treatment/intervention group then this
Table 2. Commonly encountered examples of analytical controls
Control type Purpose
QCs Qualitative QCs typically indicate whether specific aspects of the
experimental and/or analytical procedure work in the intended ways,
and are often included in the same analytical run used to collect study
data. For example, a negative control may be a sample or unit that is
known to be negative for the outcome and, hence, should assign
a negative measurement in the assay. In contrast, a positive control
would be expected to assign a positive result.
Quantitative QCs are used to monitor the performance of a quantitative
measurement system and ensure that it is performing within acceptable
limits. Typically quantitative QC samples are run at two or more
concentrations across the range of the assay and interpreted using
graphical and statistical techniques, such as Levy-Jennings plots and
Westgard rules. QC materials are generally not used for calibration in
the same process in which they are used as controls.
In instances where any QC checks fail, certain aspects of the
experimental procedure may have to be altered in order to remedy the
problem or one or more units associated with the violation may have to
be reprocessed until satisfactory checks are achieved.
Comparative/normalisation controls These can be alternative physical or biochemical parameters measured
alongside the analyte of interest usually within the same sample, for the
purposes of normalisation and/or correction. For example, in RT-PCR
housekeeping genes are usually amplified as well as targets of interest,
with the final output expressed as a ratio between the target and the
housekeeping gene.
DOI: 10.7554/eLife.05519.011
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would support a decision to continue with a larger
hypothesis testing study (Piantadosi, 2005).
Sample size calculations rely on various con-
ditions and assumptions. We need to state which
assumptions we have made and justify why it is
fair to make them. In a hypothesis testing
framework, once we have identified the form of
the primary outcome (e.g., binary, continuous, or
time to event) and how we propose to compare
the groups (e.g., a relative risk; difference
between group means; hazard ratio, etc) we
can discuss what the minimum important effect
size might be. Deciding upon the magnitude of
effect size to use in a sample size calculation can
be difficult. The most common strategy involves
attempting to define the minimum meaningful
difference. This approach does not require prior
knowledge as the investigator should choose the
smallest effect size they would be willing to miss
(if there was a true difference). This can be an
inherently subjective task, and an effective
strategy may involve estimating the required
sample sizes over a range of possible effect sizes.
For common and well-studied clinical out-
comes such as blood pressure or body mass
index, the variability of the outcome in the
population being studied (as well using the
planned means of measurement) are usually well
established. If researchers do not have data on
the outcome of interest then it may sometimes
be possible to obtain estimates of variability from
similar published studies. Using the literature to
inform a sample size calculation can be more
convenient than performing a pilot study and, if
multiple suitable estimates are available, this will
provide a range for the expected level of
variability. Nevertheless, external estimates of
the variability may not necessarily be directly
comparable to the potential level of variability in
a new and independent study—especially where
there are differences in procedure and/or meth-
ods of measurement.
Studies that involve any repeated and/or
replicated measurements on each unit are influ-
enced by multiple sources of variation. For
instance, measurements taken across experimen-
tal units over time are influenced by ‘between
time’ and ‘between unit’ components of varia-
tion. Any sample size calculation for a study
involving repeated or replicate measurements
therefore requires estimates of each variance
component in order to accurately predict the
required sample size. In complex study designs
involving multiple sources of variation, it is
unlikely that estimates of all applicable variance
components will be available from the literature.
A pilot study of interim analysis of the data may
therefore be required in order to provide
a meaningful estimate of the required sample
size (see ‘Interim analysis’ section). Sample size
calculations for these studies, by definition, may
also be more complex, often requiring a compu-
tationally intensive method such as estimation by
Monte Carlo simulation.
Example(s): The study in Box 1 plans to take
repeated measurements on each experimental
unit over time, and to test each combination of
components in triplicate. Each additional mea-
surement of the flow rate adds information to
the study and will, up to a certain point, help to
increase the statistical power of the study. An
estimate of each source of variance would be
required to accurately estimate the power (or
required sample size) for this study, which may
not be readily available in previous publications.
As such, a pilot phase might be built into this
study in order to inform a sample size calcula-
tion (see ‘Interim analysis’ section later). In
addition to estimates of the applicable ‘variance
components’, any sample size calculation would
also require a definition of the desired type I and
type II error rates. Furthermore, the ‘minimum
meaningful difference’ would also need to be
defined. As this study may be conducted as an
equivalence test, the minimum difference might
be taken as the ‘equivalence limits’ in which the
95% confidence interval for the difference in
flow rates must lie (i.e., previously defined as ±
0.6 ml/hr).
Planned analysis
Data assessment and preparation
QC criteria
QC procedures aim to assess the validity of any
data collected in a study, and to detect any errors
that may have occurred, thereby helping to avoid
the potential effects of any biases or unwanted
variation that may arise. Often, QC procedures
involve analysing control samples included in the
design of the study (see ‘Use of analytical controls’
section). Plans for handling data from any analyt-
ical controls therefore need to be defined upfront
so that any experiments or samples that fail QC
can be repeated or reanalysed if required.
Criteria may be set to verify that any measure-
ments taken within a study are sufficiently accu-
rate. Westgard’s rules (Westgard et al., 1981) are
an example of multi-rule criteria used to de-
termine whether an analytical run is out of control.
Another reason to set criteria is, to check
whether data from calibrators, analytical controls
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or study samples are reproducible. Thresholds
for any such criteria must be set a priori using
benchmarks from any preliminary or published
work, on the premise that if an experiment or set
of measurements does not satisfy these criteria,
components of the study may have to be
repeated or certain data points excluded.
Example(s): In the macrophage study data are
collected at multiple time points. Results may fail
QC at any one of the measurement time points
and in any assay batch. The cause of this failure
may be due to a whole plate being contaminated
before the assay, or due to a technical fault of the
measurement system. The impact of a failed plate
when longitudinal measurements are made may
be larger as this prevents further measurements
being made and calls into question prior measure-
ments before the contamination was detected. So
a full or partial repeat of the whole experiment
may be necessary. The failure of a single assay
batch may be more recoverable depending on the
proportion of missing data in measurements
needed at that time point. In the described design
there are two replicates so a sensitivity analysis
could be employed in which extreme values (e.g.,
single measurements more than 3 SD away from
the batch specific mean) are coded as missing.
Data verification
Where necessary data in the database for analysis
should be checked against its source to identify
data entry errors prior to analysis. This important
step can take time and should be incorporated
into the analysis plan.
Data normalisation/correction
Other aspects of data preparation may involve
attempting to correct for potential problems such
as known (or unknown) biases or confounding
effects. Normalisation methods are often used to
align data to an expected distribution, with the
aim of ensuring that the groups being tested are
comparable. This can involve taking into account
information on the structure of the study design
such as batch or centre numbers or by using data
from appropriate analytical controls. The planned
normalisation or correction procedure may have
implications for the subsequent analysis of the
data and should be specified in advance.
Example(s): The study in Box 3 involves several
stages of sample and/or data processing, each of
which may require implementation of specific QC
procedures. For instance, RNA quality and the
possible impact of DNA contamination need to be
assessed, with criteria potentially set to exclude
bad samples (e.g., using the RNA integrity number
score). The processes involved in quantifying the
transcriptome (e.g., using the Tuxedo suite of
software) may also be subject to data quality
issues and need to be assessed accordingly. As
RNA-sequencing can be inherently susceptible to
batch effects and/or other unwanted sources of
variation, data correction techniques such as PEER
(Stegle et al., 2012) may also be employed to
normalise data profiles across samples.
Outliers
Having performed appropriate checks that the
data are accurate and reproducible, it is good
practice to use a combination of descriptive and
graphical methods to assess the distributions of
your study variables to check for outliers. It is not
good practice to routinely discard such outliers
from analysis; however, having performed the
primary analysis on the full dataset, one can
perform sensitivity analyses that exclude outliers,
to show how they might be influencing the
conclusions. Where possible the criteria for
identifying potential outliers should be specified
in advance of obtaining the results.
Statistical methods
Early consideration of the statistical methods helps
to ensure that a study’s objectives will be reliably
addressed. It allows study design to be optimised
by enabling an appropriate sample size calculation
to be made, and ensures that the resulting data
will be suitable for the most appropriate statistical
analysis. Specifying firm details about the antici-
pated statistical methods upfront, including the
analytical strategy for any secondary research
questions or potential subgroup analyses, can also
help to avoid biases at the analysis and reporting
stages. In particular, it helps guard against the
selective reporting (or ‘cherry picking’) of favour-
able results, and provides full transparency about
the initial analysis plan. A further advantage of
clarifying details about the planned statistical
analyses upfront is that, where applications for
funding will be submitted, it may provide an
opportunity to cost in time for any necessary
statistical support that will be required, such as for
regular integrated discussions with a statistician or
for the dedicated statistical analysis. This section
of the checklist details the key analytical consid-
erations that should be decided upon upfront
during study planning.
Describe the different analyses to be
performed
The methods that will be used can fundamentally
impact on the types of inferences that can be
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drawn from a study. As such, these should be
decided upon upfront, along with related details
such as any model terms or covariates that will be
considered and the specific tests or comparisons
that will be performed. If data require a trans-
formation prior to the analyses then all such
transformations need to be documented and
clearly justified. These aspects of the statistical
methodology all have implications for the sample
size calculation, and can influence the scope and
the validity of the findings. As different statistical
methodologies rely on different assumptions, plans
to assess the validity of these assumptions should
also be made. If any of the assumptions do not hold
then the results of the analysis may be misleading.
For such situations it may be that a simple data
transformation will suffice, if not alternative meth-
ods may be required for which additional statistical
support may need to be sought. Sensitivity analyses
can provide a means of assessing the dependency
of research findings upon the assumptions, and can
help to strengthen any conclusions being made.
Example(s): The study in Box 1 measures flow
rates over time on each pump-catheter combi-
nation, and plans to replicate each experiment
three times on a particular experimental unit. As
such, the measurements collected in this study
are not independent; flow rates recorded close
together in time may be more similar than those
recorded at different times, whereas the meas-
urements gained in a particular experiment or
unit may be more similar than those measured
across experiments or units. Many conventional
statistical methods assume that all observations
are independent and, hence, may produce mis-
leading results if applied in this study and pseudo
or false replication occurs when there is such
a mismatch between the experimental design
and the statistical analysis method (Hurlbert,
1984). An appropriate method for handling
repeated measurements would instead be re-
quired, such as a mixed-effects model. Mixed-
effects models handle non-independent meas-
urements (sometimes referred to as ‘pseudo-
replicates’) by including ‘random effect’ terms.
Any parameters or factors of interest that need
to be tested—such as the pump and catheter
effects—would be included as ‘fixed effects’.
After fitting such a model, planned comparisons
can be made to assess the key hypotheses; for
example, to quantify: (1) the difference between
new and existing pumps; (2) the difference
between new and existing catheters; and (3) the
difference between each combination involving
a new pump and/or catheter and the combina-
tion of existing pump and existing catheter.
Missing data
Planning to handle any missing data that may
arise upfront can help to avoid potential prob-
lems and bias at the analysis stage. Missing data
may arise for any number of reasons, but any
obvious problems that could occur should be
anticipated in advance and plans made to deal
with their possible effects. Depending on the
study design, it may be possible to guard
against missing or inaccurate data by monitor-
ing data quality as it accrues; pilot studies are
a good way of identifying potential issues
before the full study begins.
Example: In the elastomer pump example,
measurements were to be made automatically
over a period of 48 hr. If for any reason the
equipment were to fail during this period,
longitudinal data would be missing from the
point of failure onwards. In this example, use of
a mixed-effects model would allow for the
inclusion of incomplete longitudinal datasets; in
contrast, if an alternative method such as
repeated-measures ANOVA were used, sets with
missing data would have to be excluded, re-
ducing power, or the missing values would need
to be imputed, possibly introducing bias depend-
ing on the methods used.
Multiple testing
Running multiple tests within a study usually
requires some form of correction for the number
of tests being made (often referred to as
accounting for ‘multiplicity’). This guards against
the increased chance of obtaining positive
results just by chance as you increase the
number of tests or observations being made
on the same data. A type 1 error rate of 5%, that
is, testing at p < 0.05, suggests that 1 in every
20 tests will be significant simply by chance. The
two most commonly used forms of adjustment
involve controlling either the ‘family-wise error
rate’ or the ‘false-discovery rate’ (FDR). The
family-wise error rate assumes a given probabil-
ity of obtaining one or more false-positive
results within a set (or ‘family’) of tests. Often,
a 5% family-wise error rate is used—meaning
that, on average, only 5 out of 100 repetitions of
the complete set of tests would contain at least
one false-positive result. In contrast, the FDR
assumes—usually less stringently—that a given
proportion of a particular set of positive results
are false-positive. Deciding upon the means of
adjusting for multiplicity—including defining the
number of tests to adjust for and/or what
constitutes a single family of tests, can be
a contentious issue.
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Example(s): In the study in Box 2, 10 cytokines
will be tested, and multiple comparisons of
treatments will be made for each cytokine. A
suitable adjustment for multiplicity would there-
fore account for the number of comparisons of
treatments made for each cytokine, and the
number of cytokines tested.
In the Box 3 example, a large number of
transcripts will be tested for association with
hypertensive status, creating a multiple testing
issue. Many of the transcripts are expected to be
highly correlated with one another, however,
while most adjustments for multiplicity assume
that all tests being corrected for are indepen-
dent. In this scenario, adjusting for the full
number of transcripts tested would be conserva-
tive, and could—arguably—unfairly reduce the
statistical power of the study. As such, it may be
reasonable to use a less conservative adjustment
in this study, or to seek a more sophisticated
approach that can better account for the number
of independent tests being made.
Interim analysis
Properly planned interim analyses can
strengthen the quality of the data and/or
reduce costs, because they potentially allow
for the sample size calculation to be updated
with more accurate information, or for data
collection to be stopped early. However, they
must be planned in advance; ad hoc analysis of
data before the final sample size is reached
risks falsely rejecting the null hypothesis,
due to multiple testing or to obtaining a biased
estimate of the effect size in too small
a sample.
Having discussed the study design with
reference to the framework, there may be
elements that cannot be addressed immediately
with confidence. For example, data underpinning
the sample size calculation may be of uncertain
quality/applicability, or suggested adjustments
to the methods may need to be trialled for
feasibility. An interim analysis after a certain
proportion of the data had been collected would
allow adjustments to the sample size to be made,
or potentially would allow data collection to stop
altogether. Under some circumstances interim
analysis would require breaking of a blind, or
inflation of the final sample size required. For this
reason interim analyses should be planned fully in
advance, with consideration given to the practical
implications of performing the analysis, and rules
should be defined which determine the circum-
stances under which data collection should
continue.
Example(s): The study in Box 1 has not been
subject to a formal sample size calculation due to
a lack of available data on the magnitude of the
various components of variation planned into the
design (e.g., the variation in flow rates between
time-points in a particular experiment on a particular
unit, the variation between experiments, and the
variation between units). As such, it would be
desirable to plan for an interim analysis of the data
during the study in order to estimate the sample size
required to run any equivalence tests with sufficient
power. If the interim analysis solely involved esti-
mating variance components, it would not be
necessary to break the blinding of the interventions
or add to any multiple testing burden. However, if
the experimenters wished to assess for equivalence
at an interim stage of the study, the planned sample
size would need to be increased further in order to
properly allow for this. Note that, contrary to these
plans, this entire study may instead be considered to
be a pilot for a larger future study. In this scenario, it
may not be worth conducting any interim analyses;
the resources planned for the current study may
already be fixed, with no scope for increasing the
sample size if required.
Replication and/or validation
Validation and/or replication of the results
provides valuable support to research findings.
Validation usually involves using a different
method and/or technique to confirm data that
has been obtained—it thereby helps to guard
against any biases or confounding associated
with measurement and/or processing. In con-
trast, replication usually refers to reproducing
results in an independent dataset (such as an
additional set of samples that were not included
in the original analysis). Replication can help
guard against confounding associated with the
experimental/sampling units, and also protects
against statistical issues such as ‘overfitting’ and
‘The Winner’s Curse’.
Example(s): The study in Box 3 may be
considered a ‘hypothesis generating’ study
whereby it aims to identify genes and biological
pathways that may be associated with hyperten-
sion. Findings from hypothesis generating studies,
by definition, require subsequent confirmatory
work in order to reaffirm any findings. Confirma-
tion of findings may be achieved by replicating
any positive results in an independent study or an
independent set of patients. Validation of the data
may also be desirable, particularly if any QC
checks highlight any potential problems with the
data such as batch effects. This may be achieved,
for example, by reanalysing any interesting
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genetic variants using another technology such as
a genotyping array.
Reporting results
Once a well-designed laboratory study has been
completed, it will need to be reported to a high
standard to enable future reproduction of the
results. There are a wide range of publications
available which give detailed instructions on how
best to report the results of different types of
studies. Many journals now require authors to refer
to specific guidelines for certain research designs.
It is not our intention to give an exhaustive list
here, as new or updated guidelines are released
with regularity. However, authors should search
for relevant guidelines when preparing for
publication; the Enhancing QUAlity and Trans-
parency Of health Research (EQUATOR) network
website is an excellent place to start, featuring
a searchable library which aims to include all
reporting guidelines published since 1996 (www.
equator-network.org).
Example(s): If the elastomer pump study in
Box 1 was treated as an equivalence study then
many of the recommendations in the CONSORT
extension for equivalence clinical trials would be
relevant.
Summary
The RIPOSTE framework aims to reduce irrepro-
ducibility in laboratory based research by en-
couraging early discussion of study design and
analysis within a multidisciplinary team including
statisticians. We seek to steer discussions within
research teams towards addressing key aspects
of experimental design and analysis at the
earliest stages of a study, and believe that this
increased focus on planning will lead to more
rigorous research and ultimately reduced wast-
age in preclinical research.
Lack of reproducibility is not the sole reason
for wastage within laboratory studies. In January
2014 the Lancet printed a special issue focussing
on how to increase value and reduce waste in
medical research (Macleod et al., 2014). It has
been claimed that much of the waste is due to
incomplete and unusable results (Chalmers and
Glasziou, 2009). The problem of poor research
practice and documentation is widespread and
entrenched in the scientific culture (Collins and
Tabak, 2014). Currently scientific rewards are
disproportionately high for being the first to
publish, and this pressure has played a major part
in generating the problems with reproducibility
that are now being highlighted (Begley, 2013;
Ioannidis, 2014).
A number of recent initiatives have drawn
further attention to these critical issues and pro-
posed strategies to address and change the
scientific culture. The common themes emerging
from these initiatives are to improve training on
experimental design and analysis, to involve
experienced statisticians at all stages of design
and analysis, to raise awareness at grant review
stage of aspects of design such as randomisation
and blinding, and to reward good quality, well
designed research. Ioannidis et al. (2014) make
three broad recommendations to improve study
design, conduct and analysis. The first of these is
to make study protocols publicly available in-
cluding the raw data and analytical algorithms. The
second promotes raising the profile of defensible
research proposals within well-trained research
teams. The third is to reward reproducible
practices through funding and academic recogni-
tion. In the same special issue of the Lancet,
Glasziou et al. (2014) recommend that funders
should support and encourage their research
institutions to share research protocols and study
materials and ultimately to promote high quality
complete reporting. At publication the emphasis
must move towards reporting results in which they
have confidence (these will often be negative) in
detail, rather than selectively reporting the details
of the positive results which, if spurious, will serve
to misguide the research community. Several
recent incentives to promote direct replication
research are beginning to make an impact with the
publication of registered reports (Nosek and
Lakens, 2014). In this framework journals agree
to accept a future publication based on accep-
tance of pre-registered proposals and prior to any
data generation.
In addition to the above initiatives, there has
also been a recent push for greater publication of
raw data. The PLoS journals, for example, imple-
mented a new data policy earlier this year
stipulating that authors must, wherever legally
and ethically possible, share all data, metadata
and methods that underlie any research findings
offered for publication (Bloom et al., 2014). Data
must be deposited in a public repository, uploaded
online in supporting files to accompany a manu-
script, or made available upon request; any failure
to ensure that sufficient provisions to share have
been made can be grounds for rejection. In the US,
the NIH also intends to promote greater access to
raw data, requesting that funding applications
include a Data Discovery Index to enable any
unpublished data to be more easily located,
accessed and referenced by other researchers in
any future work (Collins and Tabak, 2014).
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This NIH initiative has been supported by recent
calls to prospectively register laboratory studies
(Hooft and Bossuyt, 2011; Altman, 2014). Regis-
tering studies upfront would necessitate that any
deviations from protocols are both documented
and justified, and would ensure that protocols are
well thought out at an early stage (i.e., prior to
registration). It would likely also significantly im-
prove the transparency of research, as was seen
following the implementation of a similar initiative
in 2005, which sought to introduce a requirement
to prospectively register certain types of trials
(Hooft and Bossuyt, 2011). Registering studies
and reducing bias against publication of negative
results will also help to ensure that replication
studies with negative findings receive the appro-
priate attention amongst the scientific community.
These initiatives suggest the need for a major
culture change within preclinical research; tack-
ling these issues will require effort on multiple
levels. The shift to making statisticians an
integral part of the research team rather than
to be consulted in isolation will be challenging.
Statisticians’ knowledge and experience of
experimental data and the laboratory environ-
ment are highly variable. Scientists may be
reluctant to work with statisticians in this way
due to variable experiences in the past. The
RIPOSTE framework has been designed to
support this shift and help scientists and
statisticians alike form a deeper understanding
of the issues surrounding the reproducibility of
laboratory research. This should ensure that the
considerations relevant to a particular study can
be addressed efficiently with greater confidence
on both sides. To allow for a greater involve-
ment of statisticians in the study design process,
additional funds will be needed and this will
require commitment from funding bodies. We
recommend that statisticians be considered an
integral part of the research team wherever
possible, and that they should be involved at the
planning stages of studies. We encourage use of
our framework for all laboratory research
studies and not just those seeking funding. In
conjunction with other initiatives (Collins and Tabak,
2014) the RIPOSTE framework can be a useful tool
in combating irreproducibility of preclinical study
results, offering a powerful riposte to the criticisms
regarding wastage in laboratory research.
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